All News
The impact of SGLT2-inhibitor on SLE outcomes
Since chronic kidney disease is one of the strongest CV risk factors, any new strategy to reduce proteinuria and avoid a decline in renal function may likely improve patient outcomes. In large cardiovascular outcome trials, the use of a fairly new-kid-on-the-block therapy, sodium–glucose cotransporter-2 inhibitors (SGLT2i) appear to be both cardio and renal-protective. Would the use of SGLT2i have the same impact in SLE?
Read Article
ACR 2023 – Day 4 Report
The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations. Here’s a list of the late breakers; below, I provide commentary on the ones that caught my attention.
Read Article
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract reports from Monday, 11/13 at #ACR23.
https://t.co/yIYYI7IVBD https://t.co/86Nt1mVha8
Dr. John Cush RheumNow ( View Tweet)
Monitoring the Effect of Upadacitinib Therapy with a Smart Watch?
https://t.co/z6durHZ57R https://t.co/wSJiWNOx9M
Dr. John Cush RheumNow ( View Tweet)
Lupus Topic Panel
Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most interesting lupus studies presented at #ACR23.
https://t.co/QWR17kOkHD https://t.co/jpaUI2X2Fc
Links:
Dr. John Cush RheumNow ( View Tweet)
Will CAR T Cells also treat RA?
Dr. Jonathan Kay reports on abstract 0424 from #ACR23
https://t.co/xPMmVNZdAC https://t.co/8b3AmjzvML
Dr. John Cush RheumNow ( View Tweet)
Methotrexate: shall we split up?
Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg.
https://t.co/txCIkgtvzP https://t.co/Mk8FLy4jO3
Dr. John Cush RheumNow ( View Tweet)
How do we manage difficult discussions about pregnancy in RA?
Most rheums know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though...
https://t.co/cXtqqVv6fp https://t.co/k5afTUKYf8
Dr. John Cush RheumNow ( View Tweet)
L20 at #ACR23
Phase 3 RCT of #Telitacicept vs. placebo in #RA
☝🏻B-cell neutralization by targeting BlyS and APRIL
✅ better ACR20 and 50 response at W24
✅ favorable structural response
✅ good safety profile
❓ few seronegative patients
A new small molecule to treat #RA?
PAJ https://t.co/fyrqAya41e
ARD & RMD Open ARD_BMJ ( View Tweet)
#ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia:
👉🏻CVD is not a signif mediator b/w RA &Dementia
👉🏻 signif synergy b/w RA & CVD on dementia (HR 2.45 vs those w/o RA&CVD)
👉🏻 ⬆️ risk of dementia in RA mostly in people with RA+CVD
#Mayoclinicrheumatology https://t.co/5kqs3HAACn
Elena MyasoedovaMD ☀️ ( View Tweet)
The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease
#ACR23
The metabolomics facility was established recently at the @UHN @UofT @SchroederInst and we are already seeing the results. @KrembilF @CRASCRRheum @UofTRheum https://t.co/Azxq3k8w5g
Nigil Haroon MD, PhD, DM, FRCPC, FRCP, MBA NigilHaroon ( View Tweet)
Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation!
#ACR23 https://t.co/P7keAoOX7M
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
🔥 HOT OFF THE PRESS for #ACR23
Effectiveness of a fourth dose of #COVID19 mRNA #vaccine in patients with systemic autoimmune rheumatic diseases using DMARDs: an emulated target trial https://t.co/bvc75BP4aG @zach_wallace_md @jeffsparks https://t.co/CAlgjvUr9X
The Lancet Rheumatology TheLancetRheum ( View Tweet)
Something to listen to on the way home from #ACR23
The last episode in a 4 part series on the environment and autoimmunity
What does silica exposure have to do with autoimmunity?
https://t.co/2Vqi22xqCw
Adam J Brown ( View Tweet)
Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG incl autoantibodies (and investigated in myasthenia).
Prof Taylor presents that it might work in CCP high titer RA at #ACR23.
#ACRambassador @ACRheum https://t.co/DqlsOv7AVI
Tue Kragstrup KragstrupTW ( View Tweet)
Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23
Feasible after early remission induction https://t.co/WwiNp8WKDC
Dr Gurdeep S Dulay ( View Tweet)
Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer
.Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs
Rohit Aggarwal ( View Tweet)
Just presented at #ACR23 by Dr Jennifer Hanberg @Jen_LS_Hanberg and published at @TheLancetRheum.!
Effectiveness of 4th mRNA COVID dose on breakthrough infection @zach_wallace_md
https://t.co/PXc2THn217
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Chikungunya - takeaway points
🪔Acute arthritis in large joints , polyarthritis and tenosynovitis in hands
🪔 Associated with travel history to Africa/Asia/Asia Pacific
🪔<5% develop chronic arthritis
#ACR23
#ACRambassador https://t.co/yzZDpy70i3
Tanmayee Bichile, MD ( View Tweet)
Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases
Pregnant women with ARDs and APS face significantly increased risks of CVEs. This increased risk is often attributed to ARDs, its medications or comorbidities associated with it.
https://t.co/KwMEwlr7Af https://t.co/vDt4B8jtt6
Dr. John Cush RheumNow ( View Tweet)
